INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim safety and ...

AvenCell Therapeutics, Inc. ("AvenCell"), a leading clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T cell therapies, today announced that it has ...

In a report released today, Peter Lawson from Barclays assigned a Buy rating to Nurix Therapeutics (NRIX – Research Report), with a price ...

In addition, the FDA awarded an Orphan Products Development grant to support the evaluation of HyBryteTM for expanded treatment in patients with early-stage CTCL, including in the home use setting.

ReSET-02 dose escalation Phase I is completedPhase II PoC randomized segment is startingNo dose-limiting toxicities, no safety or tolerability issuesThe highest dose is to be used in both ...

Thomas Blake, DDS, is a respected general dentistry practice serving the Santa Barbara, CA, area. Dr. Blake specializes in biomimetic, restorative, and cosmetic dentistry. The practice is located at ...

Amplify Publishing is thrilled to announce the release of Healing Healthcare: Evidence-Based Strategies to Mend Our Broken System, a new book co-authored by international keynote speakers on workforce ...